Recce Pharmaceuticals (ASX:RCE) has announced that it has received Human Research Ethics Committee (HREC) approval to start its Phase 1/2 clinical trial assessing R327 as a spray-on, broad-spectrum antibiotic therapy for mild skin and soft tissue diabetic foot infections.
Ethics approval for Pharmaceuticals Receives' new diabetic foot ulcer study
December 11, 2022 Australian Biotech
Latest Video
New Stories
-
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech -
Government review and action timelines are in 'dog years' compared to AI
August 13, 2025 - - Latest News -
Australia is not alone in tripping over reform of medical device funding frameworks
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech